资讯

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Phase 2/3 Wave II Clinical Study to Begin in 2026 Completion of Financing to Support Registration Program MONTREAL, Sept. CNW ...